SOLID ORAL DOSAGE FORMS OF GONADOTROPIN-RELEASING HORMONE ANTAGONIST COMBINATION
VE6142021000107SUndetermined Publication Date: 2022-02-17MYOVANT SCIENCES GMBH
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- VE · VE
- Patent Type
- Designs
- Current Assignee / Owner
- MYOVANT SCIENCES GMBH
- Filing Date
- 2021-05-27
- Publication Date
- 2022-02-17
Need to check novelty before this filing date? Find Prior Art
Description
This description includes combination solid oral dosage forms containing 40 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothiene[2,3-D]pyrimidin-6-yl)phenyl)-N-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof, and hormone replacement therapies. Processes for manufacturing and using the solid oral dosage forms are also provided.